Asymchem Laboratories Tianjin CoASLTY 72 Equity-to-Asset is 0.87 as of Mar. 2026, which is 6% above its 10-year median of 0.82. GuruFocus rates ASLTY with a GF Score™ of 72/100 and a GF Value™ of $4.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,415 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks better than 76.89% on this metric.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Equity-to-Asset or its related term are showing as below:
ASLTY'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.64 Med: 0.82 Max: 0.89
Current: 0.87
During the past 13 years, the highest Equity to Asset Ratio of Asymchem Laboratories Tianjin Co was 0.89. The lowest was 0.64. And the median was 0.82.
ASLTY's Equity-to-Asset is ranked better than 76.89% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASLTY: 0.87
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Asymchem Laboratories Tianjin Co Equity-to-Asset Related Terms
Asymchem Laboratories Tianjin Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Equity-to-Asset Chart
ASLTY vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Equity-to-Asset falls into.
Asymchem Laboratories Tianjin Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is near median its historical median of 0.82. Over the past decade, Asymchem Laboratories Tianjin Co's Equity-to-Asset has ranged from 0.64 to 0.89. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #327 out of 1415 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Asymchem Laboratories Tianjin Co's Equity-to-Asset too high?
Asymchem Laboratories Tianjin Co's current Equity-to-Asset of 0.87 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 0.89. The Biotechnology industry median Equity-to-Asset is 0.68. Asymchem Laboratories Tianjin Co's value of 0.87 is 27.9% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #327 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #327 out of 1415 companies for Equity-to-Asset. This places Asymchem Laboratories Tianjin Co in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Asymchem Laboratories Tianjin Co's value of 0.87 is 27.9% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own Equity-to-Asset has ranged from 0.64 to 0.89 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.68, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Equity-to-Asset of 0.87 is 27.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Equity-to-Asset is 0.87, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.65, compared to a current price of $6.37 — trading 37% above its estimated fair value. The current Equity-to-Asset is 0.87, which is near median its 10-year median of 0.82 and 27.9% above the Biotechnology industry median of 0.68. Asymchem Laboratories Tianjin Co's overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 37% above its estimated GF Value™ of $4.65.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Equity-to-Asset: 0.87 (near median its 10-year median of 0.82)
GF Value™: $4.65 vs. price of $6.37 (37% above fair value)
Industry Position: 27.9% above the Biotechnology median (#327 of 1415)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
72GF Score
Get the complete analysis for ASLTY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
